StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Ashish Bahety, Profitmart Securities

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byAshish Bahety, Profitmart SecuritiesHorizon: NA (inferred Swing (≤2wk))23 Oct 2026via CNBC Awaaz.

Entry₹1,236.2Inferred
Target₹1,280
Total upside +3.54% (call closed)
Stop loss₹1,225-0.91% risk
Exit₹1,225Stop-loss hit — time not yet verified
Stop-loss hit-0.91%
Follow Ashish Bahety for new calls(34% target hit, 235 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 4 active Swing calls on DRREDDYSee 143 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 2:04 pm IST
5 supporting2 neutral2 opposing
Supports the BUY call (5)

4 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·22 Oct · yesterday

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 2d ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 2d ago

(opens in new tab)

Dr. Reddy's Laboratories received approval from the DCGI for Zytorvi (toripalimab) in combination with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma in India.

BSE · Company Update·21 Oct · 2d ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·21 Sept · 1mo ago

Neutral / worth noting (2)

Q2 FY27 results scheduled — board meets 23 Oct 2026

BSE · Board Meeting·23 Oct · today

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 4d ago

(opens in new tab)
Weighs against the BUY call (2)

MACD below its signal line — bearish momentum

Technicals · macd·23 Oct · today

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Ashish Bahety, Profitmart Securities

Every call and its outcome